Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Ying Song

4PUBLICATIONS

3CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Econometric and statistical methods

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (4)

Sort by Publication Date:

|May 19, 2025

Cost-effectiveness of datopotamab deruxtecan in previously treated advanced nonsquamous NSCLC.

Ying Song

|May 13, 2024

Entrectinib as first-line <i>vs.</i> second-line therapy in ROS1 fusion-positive non-small cell lung cancer: a cost-effectiveness analysis.

Gengwei Huo, Ying Song, Xiongwen Chen

|Apr 12, 2024

Cost-effectiveness of pembrolizumab plus chemotherapy for advanced endometrial cancer.

Gengwei Huo, Ying Song, Peng Chen

|Apr 12, 2024

Cost-effectiveness of atezolizumab plus chemotherapy for advanced/recurrent endometrial cancer.

Gengwei Huo, Ying Song, Peng Chen

Pageof 1

Frequent Collaborators

3 joint publications

Gengwei Huo

3 joint publications

Peng Chen

1 joint publications

Xiongwen Chen

Frequent Collaborators

3 joint publications

Gengwei Huo

3 joint publications

Peng Chen

1 joint publications

Xiongwen Chen

Top Related Videos

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on : Dec 23, 2022

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on : Sep 12, 2019

See more related videos

Top Related Videos

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis

Published on : Dec 23, 2022

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on : Sep 12, 2019

See more related videos